Liquid Biopsies for Colorectal Cancer Screening: 2021 Update

article image
ARTICLE SUMMARY:

The companies vying for leadership in blood-based colorectal cancer screening seem poised for a particularly eventful year, as data emerges on their tests almost simultaneously with finalization of a CMS NCD that seems likely to secure reimbursement for high-performing assays.

2020 was a breakout year for the liquid biopsy field and liquid biopsy manufacturers are indicating that this year will be even more important for making progress on both clinical evidence and commercialization.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: